Can a national patient registry unlock the secrets of a rare muscle disease?
NCT ID NCT04001582
First seen Aug 20, 2026 · Last updated Aug 21, 2026 · Updated 1 time
Summary
This study is building a UK-wide registry of people with facioscapulohumeral muscular dystrophy (FSHD), a rare genetic condition causing progressive muscle weakness. Participants complete questionnaires about their symptoms, pain, quality of life, and medical history. The goal is to better characterize the disease in the UK and identify potential participants for future clinical trials.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- What this could lead to
- This registry could help researchers better understand FSHD's impact and speed up recruitment for future clinical trials, potentially leading to new treatments.
- What could go wrong
- As an observational registry, it does not test any treatment directly. Its success depends on patient participation and data quality, and it may not directly produce new therapies.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
About 1,018 people
The number the study aims to enrol. It can still change while the study runs.
- Started
-
May 2013
- Expected to finish
-
Jan 2040
An estimate. End dates often move.
- Lead sponsor
-
Other sponsor
The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
Participants with FSHD volunteer to participate in this study. The registry is advertised through neuromuscular disease clinics, the registry website, patient organisations and conferences and meetings throughout the UK.
- Ages
-
Children (under 18), adults (18 to 64) and older adults (65 and over)
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: \- All patients with a confirmed FSHD diagnosis (or pending diagnosis) who reside in the UK are eligible for inclusion. Exclusion Criteria: * Any confirmed NMD other than FSHD * Living outside of the UK
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Facioscapulohumeral muscular dystrophy are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The places running it
1 site. The list below names each one and where it is.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
Contacts and locations
Locations
-
John Walton Muscular Dystrophy Research Centre
RECRUITINGNewcastle upon Tyne, NE1 3BZ, United Kingdom
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can MRI reveal the hidden progression of muscular dystrophy?
- Personalized exercise program aims to boost mobility in rare muscle diseases
- New tools aim to speed up FSHD drug trials
- New tool could better track facial muscle health in rare muscle disease
- New drug aims to build muscle in rare muscular dystrophy
- FSHD patients unite: new registry aims to accelerate research and care